Monopar Therapeutics Inc. MNPR
85.24
(3.60)
(4.05%)
as of 25 Sep
- Market cap
- $602.8M
- P/E
- 0.0×
Follow MNPR
Insider Buys
alert about insiders buying in the last 12 month
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
32.48 | 29.28 | 18.15 | 18.27 | 14.28 | 12.98 | 4.21 | 4.17 | 11.47 | 51.35 |
Net Debt/EBITDA |
1.74 | 0.54 | 2.07 | 3.06 | 2.57 | 2.22 | 1.25 | 0.82 | 3.72 | 8.06 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.01 | 0.16 | 0.83 | 0.71 | 0.74 | 0.80 | 0.69 | 0.94 | 0.41 | 0.89 |
Capex/Depreciation |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (19.05%) | (265.94%) | (39.04%) | (43.23%) | (44.52%) | (52.57%) | (72.44%) | (107.19%) | (51.42%) | (14.22%) | |
| (18.49%) | (258.13%) | (37.43%) | (40.88%) | (41.72%) | (48.69%) | (62.32%) | (81.68%) | (46.09%) | (13.65%) | |
ROIC |
0.00% | (1,627.75%) | (8,132.57%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(58.38%) | (187.71%) | (47.10%) | (33.78%) | (40.35%) | (48.06%) | (104.77%) | (150.71%) | (28.32%) | (9.96%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.11) | (1.50) | (1.44) | (1.62) | (2.13) | (2.93) | (2.84) | (2.84) | (1.69) | (1.65) |
Cash per Share |
0.20 | 5.11 | 3.71 | 7.09 | 7.64 | 8.14 | 5.16 | 2.63 | 15.89 | 18.94 |
Shareholders Equity per Share |
0.27 | 5.48 | 3.72 | 6.77 | 7.16 | 7.59 | 3.97 | 2.02 | 14.52 | 18.60 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.27 | 5.48 | 3.72 | 6.77 | 7.16 | 7.59 | 3.97 | 2.02 | 14.52 | 18.60 |
Free Cash Flow |
(1.19) | (2.63) | (2.68) | (3.02) | (4.66) | (7.32) | (7.23) | (7.86) | (6.40) | (12.20) |
Working Capital |
2.03 | 8.82 | 6.85 | 12.51 | 15.62 | 18.94 | 10.04 | 5.58 | 55.04 | 137.73 |
Net Current Asset Value |
2.03 | 8.82 | 6.85 | 12.51 | 15.62 | 18.94 | 10.03 | 5.58 | 55.04 | 137.57 |
| Other line items | ||||||||||
Quick Ratio |
32.13 | 28.80 | 17.25 | 18.25 | 14.22 | 12.85 | 4.19 | 4.13 | 11.46 | 51.33 |
Depreciation/Fixed assets |
— | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 |
Cash ROIC |
(24.36%) | (14.13%) | (19.41%) | (11.68%) | (14.38%) | (18.65%) | (31.15%) | (61.14%) | (5.56%) | (4.39%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.11) | (1.50) | (1.44) | (1.62) | (2.13) | (2.93) | (2.84) | (2.84) | (1.69) | (1.65) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
0.19 | 0.19 | 0.36 | 0.56 | 0.95 | 1.38 | 2.35 | 2.44 | 2.01 | 2.49 |
Average Assets |
6.41 | 6.41 | 8.62 | 10.34 | 15.11 | 18.70 | 16.87 | 10.29 | 33.82 | 100.50 |
Average Common Equity |
6.23 | 6.23 | 8.27 | 9.77 | 14.16 | 17.32 | 14.52 | 7.84 | 30.31 | 96.43 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates